Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Klinikum rechts der Isar, TU München, (TUM), Munich, Germany. | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
This study investigates the ability of heat shock protein HSP70 to isolate and quantify circulating tumor cells (CTCs) in patients with advanced or metastatic tumors.
CTCs will be isolated from peripheral blood before antineoplastic treatment and again after three months. Isolation using HSP70 will be compared with standard CTC isolation by EpCAM.
Additionally, imaging parameters of the primary tumor (if available) and metastases will be analysed and correlations between molecular alterations and imaging parameters will be assesed.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| HSP70CTC | Isolation of circulating tumor cells by HSP70 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| CTC isolation by HSP70 | Diagnostic Test | patients will receive additional blood examinations with quantification of circulating tumor cells by HSP70 antibodies and EpCAM. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Radiographic response to initial treatment | radiographic response to treatment will be scored according to RECIST criteria and associated with the number of CTC | 3 months after study enrollment |
| Measure | Description | Time Frame |
|---|---|---|
| Correlation between number of CTC isolated with HSP70 compared to EpCAM | the number of CTCs obtained by the novel HSP70 method will be compared to the current gold standard that uses EpCAM. This will be performed for the whole cohort and separate for each tumor site | 3 months (at both CTC assessment timepoints) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
oncological patients treated at a tertiary center
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Sebastian Zschaeck, MD | Contact | +4930450650764 | sebastian.zschaeck@charite.de |
| Name | Affiliation | Role |
|---|---|---|
| Sebastian Zschaeck, MD | Charité | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Klinik für Radioonkologie und Strahlentherapie | Recruiting | Berlin | 13353 | Germany |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 40313865 | Derived | Roy AA, Pandey A, Dhas N, Hegde MM, Parekh HS, Andugulapati SB, Nandakumar K, Satish Rao BS, Mutalik S. The Confluence of Nanotechnology and Heat Shock Protein 70 in Pioneering Glioblastoma Multiforme Therapy: Forging Pathways Towards Precision Targeting and Transformation. Adv Pharmacol Pharm Sci. 2025 Apr 24;2025:1847197. doi: 10.1155/adpp/1847197. eCollection 2025. |
Not provided
Not provided
patients can sign an optional agreement that their pseudonymized imaging and genetic data will be shared on cancerimagingarchive.net
Not provided
data will be uploaded 2 years after study completion
no specific criteria except proper referencing.
Not provided
| ID | Term |
|---|---|
| D008545 | Melanoma |
| D012509 | Sarcoma |
| D002294 | Carcinoma, Squamous Cell |
| D010190 | Pancreatic Neoplasms |
| D011471 | Prostatic Neoplasms |
| D001943 | Breast Neoplasms |
| ID | Term |
|---|---|
| D018358 | Neuroendocrine Tumors |
| D017599 | Neuroectodermal Tumors |
| D009373 | Neoplasms, Germ Cell and Embryonal |
| D009370 | Neoplasms by Histologic Type |
Not provided
Not provided
Not provided
Not provided
Not provided
circulating tumor cells and biopsies
| Correlation between differential expressed radiommic parameters between primary tumor and metastases and genetic alterations of the primary tumor and CTCs |
computed tomography parameters of primary tumors and metastases will be analysed and parameters extraced that are differentially expressed between both. The same will be performed for genomic mutations and gene expression of the primary tumor and CTC. Correlation analyses will be performed to analyze if radiographic parameters resemble genetic alterations |
| 3 months (at both CTC assessment timepoints) |
| Progression free survival | Progression free survival will be evaluated with the number of CTC as variable. This will be performed for the whole cohort and separate for each tumor site | 2 years |
| Overall survival | Overall survival will be evaluated with the number of CTC as variable. This will be performed for the whole cohort and separate for each tumor site | 2 years |
| D009369 | Neoplasms |
| D009380 | Neoplasms, Nerve Tissue |
| D018326 | Nevi and Melanomas |
| D012878 | Skin Neoplasms |
| D009371 | Neoplasms by Site |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D018204 | Neoplasms, Connective and Soft Tissue |
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D018307 | Neoplasms, Squamous Cell |
| D004067 | Digestive System Neoplasms |
| D004701 | Endocrine Gland Neoplasms |
| D004066 | Digestive System Diseases |
| D010182 | Pancreatic Diseases |
| D004700 | Endocrine System Diseases |
| D005834 | Genital Neoplasms, Male |
| D014565 | Urogenital Neoplasms |
| D005832 | Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D011469 | Prostatic Diseases |
| D052801 | Male Urogenital Diseases |
| D001941 | Breast Diseases |